Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Ibrutinib has significantly improved the outcome of patients with relapsed chronic lymphocytic leukemia (CLL). Recent reports attribute ibrutinib resistance to acquired mutations in Bruton agammaglobulinemia tyrosine kinase (BTK), the target of ibrutinib, as well as the immediate downstream effector...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Liu, Ta-Ming, Woyach, Jennifer A., Zhong, Yiming, Lozanski, Arletta, Lozanski, Gerard, Dong, Shuai, Strattan, Ethan, Lehman, Amy, Zhang, Xiaoli, Jones, Jeffrey A., Flynn, Joseph, Andritsos, Leslie A., Maddocks, Kami, Jaglowski, Samantha M., Blum, Kristie A., Byrd, John C., Dubovsky, Jason A., Johnson, Amy J.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2015
Témata:
Lymphoid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4492196/
https://ncbi.nlm.nih.gov/pubmed/25972157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-02-626846
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky